Accepted Articles                   Back to the articles list | Back to browse issues page

XML Print


Molecular and cell biology research center and pediatric infectious diseases research center, Mazandaran University of Medical Sciences, Sari, Iran , jghaffari94@gmail.com
Abstract:   (551 Views)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new coronavirus pandemic disease with extremely spreadable that affects all ages of children. Incubation period of the COVID-19 is in the range of 2–14 days.  Diagnosis of COVID-19 is nasal and pharyngeal swab, sputum, stool, and blood samples for COVID-19 nucleic acid using reverse-transcriptase polymerase chain reaction (RT-PCR). Nasal swab is more sensitive and specific than a pharyngeal swab. Lung CT imaging is a confirmation complimentary method which is more sensitive than RT-PCR analysis. The mortality rate is very low in children due to COVID-19 infection. Treatment of COVID-19 basically is supportive care and home isolation considered for a 2 weeks (1). Most countries are infected. Clinical manifestations of COVID-19 are varying from asymptomatic to severe in children (2). Allergic disorders are frequent that have been increasing in the world for decades. Asthma is the most common non communicable disease in children (3). Asthma treatments could be continuing during COVID-19 infection but biological drugs should be stopped during the acute phase of COVID-19 infection (4-6).Asthmatic Patients particularly severe or uncontrolled asthma are at increased risk of producing severe COVID‐19
Full-Text [PDF 725 kb]   (285 Downloads)    
Type of Study: Letter to the Editor | Subject: Infectious Diseases
Received: 2021/03/7 | Accepted: 2021/03/7

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2021 CC BY-NC 4.0 | Journal of Pediatrics Review

Designed & Developed by : Yektaweb